
SIGA Technologies, Inc.
HealthcareNASDAQ:SIGA · NASDAQ Global Market
+$0.01 today
Vol 0.23M · Avg 0.62M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$93.8M of revenue converted into $20.3M of net income for the selected period. Gross margin is 51.1% and net margin is -99.2%, showing how much revenue survives after costs and taxes. EPS is $0.28, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $94.6M -31.8% | $138.7M -0.9% | $139.9M +26.3% | $110.8M -17.1% | $133.7M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $29.7M -5.1% | $31.3M +75.5% | $17.8M +70.9% | $10.4M -37.2% | $16.6M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $64.9M -39.6% | $107.4M -12.0% | $122.1M +21.7% | $100.3M -14.3% | $117.1M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 68.6% -8.9pp | 77.4% -9.8pp | 87.3% -3.3pp | 90.6% +3.0pp | 87.6% | 9.8% | 28.9% | 38.3% |
| Research & Development | $6.5M -47.0% | $12.3M -25.1% | $16.4M -27.1% | $22.5M +126.6% | $9.9M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $3.1M -87.6% | $25.1M +14.0% | $22.0M -37.2% | $35.1M +94.7% | $18.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $41.2M +9.9% | $37.4M -2.7% | $38.5M -33.3% | $57.6M +106.0% | $28.0M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $562.6K +4.5% | $538.4K +0.0% | $538.3K +4.0% | $517.6K -0.9% | $522.4K | $374.2M | $1.2B | $631.8M |
| EBITDA | $31.0M -59.6% | $76.6M -13.3% | $88.3M +97.8% | $44.7M -50.3% | $89.8M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 32.7% -22.5pp | 55.2% -7.9pp | 63.1% +22.8pp | 40.3% -26.9pp | 67.2% | 5.6% | 46.3% | 42.0% |
| Operating Income | $23.7M -66.1% | $70.0M -16.3% | $83.6M +95.8% | $42.7M -52.1% | $89.1M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 25.1% -25.4pp | 50.4% -9.3pp | 59.8% +21.2pp | 38.5% -28.1pp | 66.7% | 16.6% | 24.1% | 22.0% |
| Interest Income | $6.7M | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $6.7M +10.1% | $6.1M +46.5% | $4.2M +190.1% | $1.4M +554.3% | $218.9K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $30.4M -60.0% | $76.1M -13.3% | $87.8M +98.9% | $44.1M -50.6% | $89.3M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 32.1% -22.7pp | 54.8% -7.9pp | 62.7% +22.9pp | 39.8% -27.0pp | 66.8% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $7.1M -57.9% | $16.9M -14.5% | $19.7M +92.7% | $10.2M -48.5% | $19.9M | $1.3B | -$1.6B | $745.2M |
| Net Income | $23.3M -60.7% | $59.2M -13.0% | $68.1M +100.8% | $33.9M -51.2% | $69.5M | $4.9B | $4.8B | $4.7B |
| Net Margin | 24.6% -18.1pp | 42.7% -6.0pp | 48.6% +18.0pp | 30.6% -21.3pp | 52.0% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $0 -60.2% | $1 -12.6% | $1 +106.5% | $0 -50.0% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $0 -60.2% | $1 -12.6% | $1 +106.5% | $0 -49.5% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $71.6M +0.5% | $71.3M -0.2% | $71.4M -2.1% | $72.9M -3.2% | $75.3M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $71.6M -0.2% | $71.8M +0.1% | $71.7M -2.5% | $73.5M -3.7% | $76.4M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Ventyx Biosciences, Inc.
VTYX
$1.00B

Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$862.12M

Esperion Therapeutics, Inc.
NASDAQ:ESPR
$654.91M

Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
$607.79M

CytomX Therapeutics, Inc.
NASDAQ:CTMX
$484.08M

Emergent BioSolutions Inc.
NYSE:EBS
$429.28M

Aquestive Therapeutics, Inc.
NASDAQ:AQST
$414.11M

SNDL Inc.
NASDAQ:SNDL
$369.44M

Organogenesis Holdings Inc.
NASDAQ:ORGO
$301.10M

DarioHealth Corp.
NASDAQ:DRIO
$51.63M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does SIGA generate?
SIGA Technologies, Inc. (SIGA) reported $94.60M of revenue in fiscal 2025.
Is SIGA profitable?
SIGA Technologies, Inc. (SIGA) reported $23.30M of net income, with a net margin of 24.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.